Enteric fever, primarily caused by Salmonella Typhi and Paratyphi, remains a significant global health challenge, particularly in resource-limited settings. This article presents a comprehensive approach to the effective management of enteric fever, reinforcing the importance of early diagnosis, appropriate antibiotic therapy, and preventive measures.
Early diagnosis is crucial in managing enteric fever. Rapid diagnostic tests (RDTs) are gaining acceptance due to their ease of use and quick turnaround. However, their sensitivity and specificity vary. Blood culture remains the gold standard for diagnosis, although it may not always be feasible in resource-limited settings.
Antibiotic resistance is a growing concern in the treatment of enteric fever. Empirical therapy should ideally be guided by local antimicrobial susceptibility patterns. Fluoroquinolones, third-generation cephalosporins, and azithromycin are commonly used. Duration of therapy typically ranges from 7 to 14 days, depending on the patient's clinical response.
Prevention of enteric fever largely depends on improving sanitation and access to clean water. Vaccination also plays a crucial role. Both Vi polysaccharide and Ty21a vaccines are recommended for high-risk populations and travelers to endemic areas. However, their protective efficacy is not 100%, underscoring the need for complementary preventive measures.
Managing enteric fever effectively requires a multi-faceted approach. Early diagnosis, appropriate antibiotic therapy, and preventive measures are all integral components. As healthcare professionals, it is our responsibility to stay updated with the latest diagnostic tools, understand local antibiotic resistance patterns, and advocate for improved sanitation and vaccination programs. This comprehensive strategy will help us reduce the burden of this preventable disease.
1.
A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.
2.
Study Homes In on Simpler Lung Cancer Screening Criteria
3.
Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment
4.
No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy
5.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
1.
Bone Marrow Microenvironment Biomarkers in Hematologic Health
2.
Emerging Insights in Hematology for Better Care
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Expert Perspectives on Hematology
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
3.
How Multidisciplinary Teams Support Modern Cancer Care
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
5.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation